Published in J Virol on October 01, 1995
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol (1997) 2.27
Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J Virol (2005) 0.88
Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. J Virol (1998) 0.86
Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDS. PLoS One (2014) 0.75
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science (1992) 9.30
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science (1992) 5.25
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 5.08
A formalin-inactivated whole SIV vaccine confers protection in macaques. Science (1989) 3.37
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature (1990) 3.15
Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 3.13
Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol (1989) 3.05
Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J Exp Med (1986) 2.89
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83
Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire. J Exp Med (1994) 2.72
A molecular model of MHC class-I-restricted antigen processing. Immunol Today (1992) 2.55
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol (1994) 2.40
A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol (1994) 2.23
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res (1992) 1.91
Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J Gen Virol (1994) 1.77
3,3',5,5' - Tetramethylbenzidine as an Ames test negative chromogen for horse-radish peroxidase in enzyme-immunoassay. J Immunoassay (1981) 1.75
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68
Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol (1991) 1.60
Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses (1990) 1.56
Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol (1991) 1.51
An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol (1989) 1.43
Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol (1994) 1.41
Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses (1994) 1.40
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses (1993) 1.34
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol (1995) 1.33
Characterization of the human T cell receptor alpha-chain repertoire and demonstration of a genetic influence on V alpha usage. Eur J Immunol (1993) 1.33
Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol (1994) 1.32
Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques. J Immunol (1992) 1.27
Transforming activity and antigenicity of an Epstein-Barr-like virus from lymphoblastoid cell lines of baboons with lymphoid disease. Intervirology (1977) 1.25
Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS (1991) 1.23
Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies. AIDS (1993) 1.19
Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol (1995) 1.14
AIDS vaccine developments. Nature (1992) 1.11
Computer aided design and evaluation of limiting and serial dilution experiments. Int J Biomed Comput (1988) 1.10
Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol (1994) 1.10
Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J Immunol (1992) 1.10
Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. Curr Top Microbiol Immunol (1994) 1.01
Simian immunodeficiency virus as a model for vaccination against HIV. Induction in rhesus macaques of GAG- or NEF-specific cytotoxic T lymphocytes by lipopeptides. J Immunol (1994) 1.00
Predominant use of a T-cell receptor V beta gene family in simian immunodeficiency virus Gag-specific cytotoxic T lymphocytes in a rhesus monkey. J Virol (1992) 0.99
Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med (1994) 0.98
Cytotoxic T-cell epitopes in HIV/SIV infection. AIDS (1993) 0.94
Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology (1993) 0.91
Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. AIDS Res Hum Retroviruses (1992) 0.91
Genetic and functional analysis of a set of HIV-1 envelope genes obtained from biological clones with varying syncytium-inducing capacities. AIDS Res Hum Retroviruses (1992) 0.90
Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol (1994) 0.90
Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J Virol (1992) 0.84
Comparison of protection from homologous cell-free vs cell-associated SIV challenge afforded by inactivated whole SIV vaccines. J Med Primatol (1992) 0.83
Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr (1994) 0.82
Vaccine studies with the 32H reisolate of SIVmac251: an overview. AIDS Res Hum Retroviruses (1992) 0.80
Cytotoxic T-cell response and AIDS-free survival in simian immunodeficiency virus-infected macaques. AIDS (1993) 0.80
Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine (1994) 0.79
HIV-specific CD8+ T-cell immune responses and viral replication. AIDS (1993) 0.77
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet (1998) 16.30
Emerging marine diseases--climate links and anthropogenic factors. Science (1999) 10.22
A pandemic warning? Nature (1997) 8.70
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill (2012) 7.96
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol (2000) 6.96
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill (2012) 4.95
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J (1986) 3.89
Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods (1998) 3.67
Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill (2013) 2.97
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol (1997) 2.86
Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med (1988) 2.73
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine (2006) 2.59
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell (1993) 2.40
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies. Clin Diagn Lab Immunol (2000) 2.21
Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine (1998) 2.17
Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol (2000) 2.11
Haemorrhagic fever with renal syndrome. Lancet (1993) 2.09
Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07
Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol (2000) 2.07
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Canine distemper virus from diseased large felids: biological properties and phylogenetic relationships. J Gen Virol (1996) 2.06
An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol (1999) 2.06
British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med (2012) 2.05
Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology (1997) 2.03
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol (2000) 1.95
Influenza types and patient population. Lancet (1995) 1.94
Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype. Lancet (2000) 1.87
Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant (2007) 1.83
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med (2006) 1.73
Simian immunodeficiency virus (SIV) from sun-tailed monkeys (Cercopithecus solatus): evidence for host-dependent evolution of SIV within the C. lhoesti superspecies. J Virol (1999) 1.72
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother (2000) 1.66
Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis (1994) 1.65
Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol (2006) 1.64
Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region. Arch Virol (2000) 1.61
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol (1997) 1.61
Identification of virus causing recent seal deaths. Nature (1988) 1.58
Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect (2006) 1.56
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol (1995) 1.56
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. Int J Epidemiol (2001) 1.53
PCBs are a health risk for humans and wildlife. Science (2000) 1.51
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill (2014) 1.49
Canine distemper virus--a morbillivirus in search of new hosts? Trends Microbiol (1997) 1.49
Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine (2009) 1.47
Recommendations for the use of inactivated influenza vaccines and other preventive measures. Vaccine (2001) 1.47
Mass die-Off of Caspian seals caused by canine distemper virus. Emerg Infect Dis (2001) 1.46
Prevalence of Bartonella species in domestic cats in The Netherlands. J Clin Microbiol (1997) 1.44
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Herpes simplex virus type 1 (HSV-1)--induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1. Ann Neurol (2000) 1.42
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis (1998) 1.42
Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood (1994) 1.41
Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol (2000) 1.39
Production and of monoclonal antibodies to simian immunodeficiency virus envelope glycoproteins. AIDS (1991) 1.39
Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J Virol (1998) 1.39
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38
Lymphoproliferative responses in macaques immunized with inactivated SIV vaccine. AIDS Res Hum Retroviruses (1993) 1.38
Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol (1995) 1.38
Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol (2011) 1.38
HIV forensics: pitfalls and acceptable standards in the use of phylogenetic analysis as evidence in criminal investigations of HIV transmission. HIV Med (2007) 1.38
Monoclonal antibodies to polioviruses. Comparison of intratypic strain differentiation of poliovirus type 1 using monoclonal antibodies versus cross-absorbed antisera. Intervirology (1983) 1.35
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Characterization of fastidious adenovirus types 40 and 41 by DNA restriction enzyme analysis and by neutralizing monoclonal antibodies. Virus Res (1989) 1.34
An ELISA for detection of antibodies against influenza A nucleoprotein in humans and various animal species. Arch Virol (1990) 1.34
Combination of reverse transcriptase PCR analysis and immunoglobulin M detection on filter paper blood samples allows diagnostic and epidemiological studies of measles. J Clin Microbiol (2001) 1.34
Detection, typing, and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes. J Clin Microbiol (1993) 1.31
Antigenic and genetic characterization of swine influenza A (H1N1) viruses isolated from pneumonia patients in The Netherlands. Virology (2001) 1.30
Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper/cytotoxic and CD8+ cytotoxic T cell clones. J Immunol (1989) 1.29
Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J Infect Dis (1997) 1.29
New clues to the emergence of flu pandemics. Nat Med (1998) 1.28
ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine (1999) 1.28
Development of a real-time quantitative RT-PCR for the detection of HIV-2 RNA in plasma. J Virol Methods (2000) 1.28
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol (1996) 1.27